Pasithea Therapeutics

Pasithea Therapeutics EBITDA per Employee

The EBITDA per Employee of Pasithea Therapeutics (KTTA) as of Nov 21, 2026 is -1.39 M USD. In the previous year, EBITDA per Employee was -949,997.47 USD — a change of 46.37% (lower).

EBITDA per Employee

-1.39 MUSD

YoY

46.37%

Last updated:

EBITDA per Employee of Pasithea Therapeutics is 2025 -1.39 M USD. EBITDA per Employee of Pasithea Therapeutics was 2024 -949,997.47 USD. It decreases by 46.37% lower compared to the previous year.

The Pasithea Therapeutics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2020
-4,098.40 USD
Jan 1, 2021
-300,494.20 USD
Jan 1, 2022
-839,264.73 USD
Jan 1, 2023
-1.07 M USD
Jan 1, 2024
-949,997.47 USD
Jan 1, 2025
-1.39 M USD
The Pasithea Therapeutics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-1.39 MUSD+46.37%
-949,997.47USD-10.82%
-1.07 MUSD+26.93%
-839,264.73USD+179.29%
-300,494.20USD+7,231.99%
-4,098.40USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pasithea Therapeutics Stock analysis

What does Pasithea Therapeutics do? Pasithea Therapeutics Corp. generates revenue through its Therapeutics segment, which develops treatments for Central Nervous System disorders and RASopathies, including its lead product candidate PAS-004, a MEK inhibitor for RASopathies like neurofibromatosis type 1 and Noonan syndrome. The company also offers business support services via its Clinics segment to anti-depression clinics in the United Kingdom and United States. Its therapeutic pipeline includes four programs, with PAS-004 in advanced development and three others in discovery stage. The firm's primary customers are clinics seeking business support services and potential partners for its therapeutic pipeline. The company focuses on CNS disorders and RASopathies, targeting conditions such as neurofibromatosis type 1, Noonan syndrome, and LMNA cardiomyopathy. PAS-004 is designed for multiple indications, including oncology, expanding its potential market reach. The Clinics segment supports anti-depression clinics in the UK and US, providing operational assistance without direct patient care. Revenue streams are derived from therapeutic development partnerships and clinic support services. Pasithea's lead product PAS-004 targets RASopathies and oncology, with a focus on neurofibromatosis type 1 and Noonan syndrome. The Clinics segment serves anti-depression clinics in the UK and US, offering business support services. The company's pipeline includes four programs, with three in early discovery and PAS-004 progressing toward potential commercialization. Revenue is generated through partnerships for therapeutic development and service contracts with clinics. Pasithea Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pasithea Therapeutics stock

EBITDA per Employee of Pasithea Therapeutics is -1.39 M USD in 2025.

EBITDA per Employee of Pasithea Therapeutics changed from -949,997.47 USD to -1.39 M USD, representing a 46.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Pasithea Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Pasithea Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Pasithea Therapeutics

All Key Metrics — Pasithea Therapeutics